You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back

Dovato (Tivicay/Lamivudine) is now available in Ireland for the treatment of HIV-1 in adults and adolescents above 12 years of age weighing at least 40kg, with no known or suspected resistance to the integrase inhibitor class, or lamivudine. 3

DTG

For further information on any of these products see the links to the Summary of Product Characteristics available at the top of this page.

References:

  1. Cahn P et al. J Acquir Immunde Defic Syndr . 2020;83(3):310-318
  2. van Wyk J;IAS;2019;1-16
  3. Dovato Summary of Characteristics. Available at www.medicines.ie. Last Accessed:April 2020.

▼ These medicinal products are subject to additional monitoring. This will allow quick identification of new safety information.
Healthcare professionals are asked to report any suspected adverse reactions.

Trade marks are owned by or licensed to the ViiV Healthcare group of companies.